AMB-104 ADC for AML

AMB-104 leverages the clinically validated target engagement of the Company’s CSF1R monoclonal antibody, when constructed as an ADC, to target the delivery of a tumor-killing payload to treat acute myeloid leukemia (AML).

Therapeutic area

Acute myeloid leukemia (AML)

Program safety

Validated linker-payload
and target binder

First-in-class

Only agent targeting
CSF1R for AML

Next milestone

IND-enabling studies and submission

AML and unmet needs

AML is a rapidly progressing tumor that develops when at least 20% of the bone marrow cells consist of immature white blood cells (“leukemia blasts”), leading to bone marrow failure to produce healthy blood cells.

Despite available treatments, including intensive chemotherapy or venetoclax-based combinations, approximately 20-40% of newly diagnosed patients do not achieve complete recovery and more than 50% relapse within 3 years.

For relapse or refractory AML patients, some targeted therapies can be used, but a significant number of patients have no actionable biomarkers. As a result, AML remains a devastating disease in need of more efficacious and safer therapies.

Dr. Michael Andreeff at MD Anderson discusses AML

how it is diagnosed and treated, and the significant unmet needs for patients that are resistant to, or that relapse after, currently approved treatments.  

An interview with Dr. Michael Andreeff from MD Anderson

to discuss the preclinical data results that support the strategy of targeting CSF1R with the AMB-104 antibody-drug conjugate for treating Acute Myeloid Leukemia (AML)

AMB-104 ADC for the treatment of AML

CSF1R is overexpressed across different segments of the AML patient population including both newly diagnosed patients and Relapsed/Refractory patients. AMB-104 leverages the overexpression of CSF1R to target AML cancer cells with a proven cytotoxic payload and has broad application for use across a range of AML patient populations.

The development of AMB-104 for AML is supported by a robust preclinical data package that includes, among other things, confirmed overexpression of CSF1R on AML patient samples, efficient internalization into AML cells, and robust in vitro and in vivo efficacy data.

AmMax's antibody targeting CSF1R

  • Clinically validated target engagement.
  • Proven strong binding affinity and internalization in AML cells.

Proven linker

  • Linker-payload has been tested in multiple Phase 1/2 clinical studies.
  • Cytotoxic payload efficacy has been clinically validated.

Targeting Rationale of AMB-104

Monocytic expansion within AML cells drives resistance to ven/aza treatments and creates a CSF1R-targetable state

AMB-104 has the potential to address primary AML as well as relapsed/refractory (R/R) AML patients via the delivery of its toxic payload to CSF1R+ monocytic AML cells